Rotavirus infection is the most common cause of severe gastroenteritis in infants and children [1] [2] [3] . According to the World Health Organization (WHO), 2.4 million hospital admissions and 527,000 deaths annually are attributed to rotavirus infection and the estimated rotavirus related global death during 2008 was 453,000 (420,000 -494,000) child deaths 1, 4 . Because of the worldwide burden of rotavirus infection, the introduction of vaccination to prevent and minimize rotavirus associated morbidity and mortality has been a public health priority to several countries 1 .
According to the last census conducted in 2010, Bahrainis were approximately 568,399 (46%) and 666,172 (54%) of the populations were non-Bahraini, which include many workers
Impact of Rotavirus Vaccination on Viral Gastroenteritis Diseases
Jaleela S. Jawad, MBBS, ABFM, MSc, DLSHTM* Adel S. Al-Sayyad, MD, ABFM, MSc, DLSHTM** Khulood Fakhroo, DGN, CHN*** Ali Al-Muwali, BS, MSC**** and their families 5 . The total number of children under 5 years of age was 89,020, whereas the birth cohort was less than 20,000 6 .
Rotavirus infection has been a major cause of admission due to viral gastroenteritis among infant and young children in Bahrain. In a study between April 2006 to March 2007, it was found that approximately 45% of moderate to severe viral gastroenteritis among hospitalized under 5 years attributed to rotavirus infection; the rotavirus vaccine was introduced to the immunization schedule since October 2008 7 .
Safety of rotavirus vaccine in particular was a concern particularly after the withdrawal of the first licensed rotavirus vaccine in 1999 due to the association with intussusceptions No published database was found in Bahrain since the introduction of the vaccine to routine schedule to evaluate its impact on hospitalization of viral gastroenteritis.
The aim of this study is to evaluate the impact of rotavirus vaccination program in viral gastroenteritis admission among patients aged less than 5 years of age and to evaluate the intussusception incidence in relation to vaccine introduction.
METHOD
Children aged less than 5 years and hospitalized with acute gastroenteritis and intussusception based on international classification of diseases tenth revision code were included in the study.
Children less than five years of age were divided into two groups: viral gastroenteritis and intussusception; both groups were admitted to pediatric wards and reviewed from 1 January 2008 to 31 December 2012. The characteristics of patients with intussusception only were reviewed and analyzed according to age, sex, nationality and vaccination status. Children less than 5 years with bacterial gastroenteritis were excluded.
A monovalent oral Rotavirus vaccine (Rotarix) was introduced in October 2008 to routine childhood immunization schedule as two doses. The first dose is administered concomitantly with the hexavalent vaccine (DTaP,HB,Hib+IPV) and the thirteen valent pneumococcal conjugate vaccine at age of two months, while the second dose was administered at age of four months with the pentavalent vaccine (DTwP,HB+Hib), second dose of thirteen valent pneumococcal conjugate vaccine and oral polio vaccine.
On 22 March 2010, the FDA temporarily suspended Rotarix vaccine due to presence of PCV1 DNA fragments in two batches of Rotarix vaccine in USA. Bahrain decided to temporarily suspend the vaccine from March 2010 to June 2010 as precautionary measure and resumed its use after completion of safety studies.
Data was entered and analyzed using SPSS 16 statistical package. The data was analyzed to calculate the viral gastroenteritis incidence rate for children under 5 years and the incidence rate of intussusception.
RESULT
One thousand nine hundred fifty-five patients under five years of age were hospitalized from 1 January 2008 to 31 December 2012.
One thousand nine hundred one patients were admitted with viral gastroenteritis (first group 
DISCUSSION
In our study, the number of cases was fluctuating prior to vaccine introduction with maximum number of admission related to viral gastroenteritis in the year 2006 and lowest in 2001; in addition, the hospitalization rate for children under 5 years of age in the 4 years prior to vaccine introduction was 0.85% compared to 0.34% in the 4 years following vaccine introduction. The reduction over 4 years among children under 5 years of age hospitalized with acute gastroenteritis was 50%.
Studies showed that increased rotavirus vaccine coverage resulted in rapid reduction of viral gastroenteritis hospitalization among children less than 5 years 13 .
In our study, reduction in viral gastroenteritis hospitalization was found after vaccine introduction and this is supported by similar finding in other studies performed in different countries 14 .
The incidence of intussusception has been previously studied in Bahrain prior to vaccine introduction to determine the incidence; the rate was 17.8 per 100,000 per year in children less than five years and 72.4 per 100,000 per year in infants. In our study, the incidence rate was relatively lower following vaccine introduction 15 . This might be explained by the variation in the risk of intussusception over time in any country and might be related to variation in reporting. The male predominance is consistent with a previous study conducted in Bahrain 15 .
Despite the slight increase in the incidence rate of intussusception found within 31 days of rotavirus vaccination in other countries, a similar finding was not observed since the introduction of the rotavirus vaccine in our study 9 . However, this needs to be interpreted cautiously due to small population, short duration of vaccine introduction and low coverage in the year 2008 and in the year 2010. In addition, some of the intussusception cases might not have been reported to health facilities or resolved spontaneously 15 .
The study gives an overall insight of the impact of newly introduced vaccine and evaluates its continuity.
Several countries in the region estimated rotavirus disease burden; however, the vaccine was not incorporated in their schedule. This study proves that the vaccine has a positive impact on reducing viral gastroenteritis hospitalization.
This study provides baseline information that might be utilized by a decision maker to measure the impact of vaccines on decreasing morbidity related to diseases targeted by vaccination.
The study had several limitations: it was conducted in one center rather than multicenter, the overall effect of rotavirus vaccine was studied and only admitted cases were considered.
CONCLUSION
The study revealed reduction of hospitalization due to viral gastroenteritis following Rota virus vaccine introduction and no reported intussusception within 31 days of vaccination. It is advised to conduct a multicentric study to evaluate the incidence of viral gastroenteritis and intussusception following vaccine introduction. _____________________________________________ Author Contribution: All authors share equal effort contribution towards (1) substantial contributions to conception and design, acquisition, analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the manuscript version to be published. Yes.
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